title: Near-infrared optical imaging of cancer vascular remodeling after antiangiogenic therapy.
abstract: BACKGROUND
  Near-infrared diffuse optical imaging (DOSI) has been recently accepted as a method to assess tumor vascularity and oxygenation by measuring tissue hemoglobin (Hb) concentration. It is expected that DOSI could be used to monitor changes in vascularity after antiangiogenic therapy.
  
  
  METHODS
  A patient with advanced breast cancer was treated with single-agent bevacizumab followed by addition of weekly paclitaxel to it. DOSI was performed in the tumor-bearing breast and contralateral normal breast at baseline, 3, 6, 12, 24 h, and then daily for 1 week. Images of a tumor-to-normal ratio of tHb (rtHb) were constructed for identifying a tumor lesion.
  
  
  RESULTS
  Serial images of rtHb showed a tumor lesion which corresponded to a hot spot. The level of rtHb rapidly decreased within several hours after administration of single-agent bevacizumab and then persisted at low levels during treatment. From day 2, the value of rtHb gradually increased and peaked on day 5.
  
  
  CONCLUSIONS
  This trend may be explained considering sequential images of rtHb indicating the inhibition of angiogenesis due to antiangiogenic therapy. We conducted a clinical study using single-agent bevacizumab followed by neoadjuvant chemotherapy in primary breast cancer patients to understand vascular remodeling after antiangiogenic agent at very early time points using DOSI.
authors.affiliation: Department of Breast Oncology, International Medical Center, Saitama Medical University, 1397-1 Yamane, Hidaka, Saitama, 350-1298, Japan, syueda2000@yahoo.co.jp.
authors.forename: Shigeto
authors.initials: S
authors.lastname: Ueda
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Saeki
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols; D000068258:Bevacizumab; D005260:Female; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D042361:Mammary Glands, Human / Q000098:blood supply / Q000187:drug effects; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage; D013055:Spectrophotometry, Infrared / Q000379:methods*; D064726:Triple Negative Breast Neoplasms / Q000188:drug therapy / Q000473:pathology*; D066253:Vascular Remodeling
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D006454:Hemoglobins; D000068258:Bevacizumab; D017239:Paclitaxel